Elias Mai, MD, Heidelberg Myeloma Center, discusses the GMMG-HD7 clinical trial for patients with multiple myeloma.

 


Multiple myeloma is a bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.

The GMMG-HD7 clinical trial is a randomized, phase 3 study evaluating the effect of isatuximab in induction therapy with lenalidomide/bortezomib/dexamethasone (RVd) and lenalidomide maintenance in patients with newly diagnosed multiple myeloma. Isatuximab is an anti-CD38 monoclonal antibody. 662 patients were enrolled in the trial.

Following a median follow up of 47 months, 179 PFS events occurred (time from first randomization to progression or death from any cause, whichever occurred first). Isa-RVd therapy was observed to significantly prolong PFS when compared to RVd, with three year PFS rates at 83% and 75%, respectively.

Additionally, similar results were seen in treatment with Isa-RVd followed by lenalidomide maintenance versus RVd induction followed by lenalidomide maintenance. Three year PFS rates were 84% and 73%, respectively. Overall survival rates were 88% for the Isa-RVd arm and 89% for the RVd arm.

For more information, click here.

To learn more about multiple myeloma and other rare blood cancers, visit https://checkrare.com/diseases/hematologic-disorders/